ArticleLiver cancer2026
Exposure to Poly- and Perfluoroalkyl Substances and Risk of Hepatocellular Carcinoma in Male Patients with Cirrhosis Related to Hepatitis C Virus Infection.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prior studies suggest that per- and polyfluoroalkyl substances (PFAS) may increase risk of liver disease including hepatocellular carcinoma (HCC) via changes in hepatic lipid, amino acid, and glucose metabolism. However, whether PFAS promotes HCC among individuals with cirrhosis has not been examined. We examined associations of PFAS exposure and risk of HCC among patients with cirrhosis. Methods: In this nested case-control study, pre-diagnostic serum PFAS concentrations were measured using liquid chromatography-tandem mass spectrometry in 47 male patients with cirrhosis who developed incident HCC (cases) and 47 sex- and race/ethnicity-matched male cirrhosis patients who did not progress to HCC (controls). We estimated odds ratios (ORs) and 95% confidence intervals (95% CIs) using conditional logistic regression. Results: All cases and controls were male, and there were no differences in the distributions of age and race/ethnicity between matched cases and controls. Most cases and controls (81%) had hepatitis C virus, and 85% were overweight/obese. Higher levels of perfluorooctanoic acid-type compounds, including L-perfluorooctanoic acid (OR, 1.63; 95% CI: 1.00-2.74), perfluorodecanoic acid (OR, 2.16; 95% CI: 1.00-5.12), perfluorononanoic acid (OR, 4.26; 95% CI: 1.84-11.9), and perfluoroundecanoic acid (OR, 3.18; 95% CI: 1.27-8.77), were associated with increased risk of HCC. Similarly, higher levels of perfluorooctane sulfonate (PFOS) were associated with higher HCC risk but only in patients with HCV (total PFOS, OR, 1.81; 95% CI: 1.08-4.00). Conversely, higher perfluorobutanesulfonic acid levels were associated with lower risk of HCC, and there was no significant association between perfluoroethylcyclohexane sulfonate level and HCC risk. Conclusions: Exposure to higher PFAS levels was associated with an increased risk of HCC among patients with cirrhosis. These preliminary findings need to be confirmed in large studies and may provide a new insight into the mechanisms of environmental-associated HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.